<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1210">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510207</url>
  </required_header>
  <id_info>
    <org_study_id>CNBG2020003SQ</org_study_id>
    <nct_id>NCT04510207</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above</brief_title>
  <acronym>COVID-19</acronym>
  <official_title>Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Biotec Group Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>G42 Healthcare company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abu Dhabi Health Services Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Institute of Biological Products Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Institute of Biological Products Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Biotec Group Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3
      clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated
      SARS-CoV-2 vaccines in healthy population 18 years old and above.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2020</start_date>
  <completion_date type="Anticipated">September 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 16, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of COVID-19 cases after two-doses of vaccination</measure>
    <time_frame>From14 days after the second dose to 6 month after the second dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of severe cases of SARS-CoV-2 pneumonia and deaths accompanied by COVID-19 after two-doses of vaccination</measure>
    <time_frame>From14 day after the second dose to 6 month after the second dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of any adverse reactions/events</measure>
    <time_frame>28 days after each immunization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of serious adverse events (SAE)</measure>
    <time_frame>From the beginning of the first dose to 12 months after the second immunization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>14 days after full course of immunization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The four-fold increase rate of anti-SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>14 days after full course of immunization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>14 days after full course of immunization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>28 days, 3rd month, 6th month, 9th month, and 12th month after 2 doses of immunization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 4-fold increase rate of anti-SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>28 days, 3rd month, 6th month, 9th month, and 12th month after 2 doses of immunization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>28 days, 3rd month, 6th month, 9th month, and 12th month after 2 doses of immunization</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>the anti-SARS-CoV-2 neutralizing antibody protective level against COVID-19</measure>
    <time_frame>14 days after 2 doses of vaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The occurrence of ADE</measure>
    <time_frame>From the beginning of the first dose to 12 months after the second immunization</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45000</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Investigational Vaccine1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by WIBP according to the immunization schedule of D0 &amp; D21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational Vaccine 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by BIBP according to the immunization schedule of D0 &amp; D21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 2 doses of Placebo according to the immunization schedule of D0 &amp; D21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated SARS-CoV-2 Vaccine (Vero cell)</intervention_name>
    <description>The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP</description>
    <arm_group_label>Investigational Vaccine1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated SARS-CoV-2 Vaccine (Vero cell)</intervention_name>
    <description>The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by BIBP</description>
    <arm_group_label>Investigational Vaccine 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo of inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy subjects aged 18 years old and above.

          2. By asking for medical history and physical examination, the investigator judged that
             the health condition is well.

          3. Female subjects of childbearing age are not nursing or pregnant at the time of
             enrolment (negative urine pregnancy test) and have no family planning within the first
             3 months after enrolment. Effective contraceptive measures have been taken within 2
             weeks before inclusion.

          4. During the whole follow-up period of the study, be able and willing to complete the
             whole prescribed study plan.

          5. With self-ability to understand the study procedures, the informed consent &amp;
             voluntarily sign an informed consent form and be able to comply with the requirements
             of the clinical study protocol.

        Exclusion Criteria:

          1. Confirmed acute cases of SARS-CoV-2 Infection.

          2. Have a history of SARS, MERS infection (self-report, on-site inquiry).

          3. Positive urine pregnancy test result.

          4. Fever (body temperature &gt; 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose,
             pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14
             days before vaccination.

          5. Axillary body temperature &gt; 37.0 ℃ before vaccination.

          6. Previous severe allergic reactions to vaccination (such as acute allergic reactions,
             urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known
             ingredients of inactivated SARS-CoV-2 vaccine have occurred.

          7. Has a history of convulsion, epilepsy, encephalopathy or mental illness or family
             history.

          8. With congenital malformations or developmental disorders, genetic defects, severe
             malnutrition, etc.

          9. With severe liver diseases, severe kidney diseases defined as eGFR less than 60,
             uncontrollable hypertension (systolic blood pressure &gt;150 mmHg, diastolic blood
             pressure &gt; 90 mmHg), diabetic complications, malignant tumors, various acute diseases,
             or acute attack period of chronic diseases.

         10. Has been diagnosed with congenital or acquired immune deficiency, HIV infection,
             lymphoma, leukemia or other autoimmune diseases.

         11. With known or suspected diseases include acute respiratory diseases (e.g. influenza
             like illness, acute cough, sore throat), severe cardiovascular diseases, liver and
             kidney diseases, and malignant tumors.

         12. Has a history of coagulation dysfunction (e.g. Coagulation factor deficiency,
             coagulation disease).

         13. Receiving anti-TB therapy.

         14. Patients receiving immunotherapy or inhibitor therapy within 3 months (continuous oral
             or infusion for more than 14 days).

         15. Live attenuated vaccine is inoculated within 1 month before this vaccination, other
             vaccines are inoculated within 14 days before this vaccination.

         16. Received blood products within 3 months before this vaccination

         17. Received other research drugs within 6 months before this vaccination.

         18. Other circumstances judged by investigators that are not suitable for this clinical
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walid A Zaher, MD, MSc,PhD</last_name>
    <role>Study Director</role>
    <affiliation>G42 Healthcare company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunkai Yang, Prof.</last_name>
    <phone>+8613601126881</phone>
    <email>yangyunkai@sinopharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bahrain International Exhibition &amp; Convention Centre Affiliated to Salymynia Medical Complex S</name>
      <address>
        <city>Sanabis</city>
        <country>Bahrain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manaf M Alqahtani, Prof.</last_name>
      <phone>+9733966000</phone>
      <email>drmanaf@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince Hamza Hospital</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Majed Nusair</last_name>
      <phone>+982799501230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaikh Khalifa Medical City, SEHA</name>
      <address>
        <city>Abu Dhabi</city>
        <zip>51900</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nawal AI Kaabi, MD</last_name>
      <phone>+971505595521</phone>
      <email>nalkaabi@seha.ae</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Al Qarain Primary Health Care Centre-MOHAP</name>
      <address>
        <city>Sharjah</city>
        <zip>61545</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Najiba Abdulrazzaq, Doctor</last_name>
      <phone>+971506451881</phone>
      <email>Najiba.Abdulrazzaq@mohap.gov.ae</email>
    </contact>
  </location>
  <location_countries>
    <country>Bahrain</country>
    <country>Jordan</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>SARS-CoV-2 Vaccine</keyword>
  <keyword>Coronavirus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

